Sun Pharmaceutical Industries Ltd. (Sun Pharma) is an international specialty pharmaceutical company. The Company’s product portfolio consists of four categories of products: India branded generics, US generics, international branded generics and active pharmaceutical ingredients (API). The products of the Company are prescribed in therapy areas like cardiology, psychiatry, neurology, gastroenterology, diabetology and respiratory. The products manufactured by the Company include Supatret, Winolap, Donamem, Exmasin, Lenzest, Octride Depot 10, Carcidox, Tyrogef, Cernos depot, Milnorm, Levipil, Exzilor and Macorate. The Company’s subsidiaries include Sun Pharma Global Inc. BVI., Sun Pharma Global-FZE, Sun Pharmaceutical (Bangladesh) Ltd., Sun Pharmaceutical Peru S.A.C. and Sun Farmaceutica Ltda-Brazil. In November 2008, the Company, along with its subsidiaries, completed the acquisition of Chattem Chemicals, Inc.

Bilcare was founded in 1995 by chairman Mohan Bhandri. Billing consumers is one of the few things that Bilcare doesn't care about when it comes to pharmaceuticals. The company is a full-service pharmaceutical development company whose services include discovery and research, clinical trial supplies manufacturing and distribution, and clinical trials management. The company also develops and manufactures prescription pharmaceuticals packaging and packaging machines. Research and manufacturing facilities are in operation in India, Singapore, the UK, and the US; additional international offices are scattered around some 30 countries worldwide. Clients include GlaxoSmithKline, Johnson & Johnson, and Pfizer.

Banner Pharmacaps, Inc., a drug delivery and specialty pharmaceutical company, engages in the research, development, and manufacture of oral dosage forms for the pharmaceutical health care industry. It develops drug delivery systems and patented technologies, including Soflet Gelcaps, a technology that enrobes tablets with a gelatin or non-animal film; LiquiSoftT Chewable Liquid-Filled Softgels, which is a chewable gel dosage form suitable for pediatric populations; Chewel, a soft chewable gelatin dosage form for pediatric populations; EnteriCare, which are enteric softgels; Versatrol, which is a controlled release softgel technology; and EcoCaps, which are non-animal softgels. It serves pharmaceutical and biotechnology, and consumer healthcare markets. The company was founded in 1994 and is headquartered in High Point, North Carolina. It has drug manufacturing facilities in High Point, North Carolina; Tilburg, the Netherlands; Olds, Canada; and Mexico City, Mexico. It has locations in Mexico, Europe, the Asia/Pacific, the United States, and Canada. Banner Pharmacaps, Inc. operates as a subsidiary of VION N.V.

Oragenics, Inc. company was founded in 1996 and is based in Alachua, Florida. Oragenics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of products and technologies associated with oral health, antibiotics, and other general health benefits. The company develops Probiora3, an oral probiotics technology that employs three natural strains of beneficial bacteria, which promote oral health; LPT3-04 for weight loss; and DPOLT or differentially protected orthogonal lantionine technology, which is a solid or liquid phase peptide synthesis platform technology that has various applications for the manufacture of commercially important bioactive peptides. It is also developing Mutacin 1140, an antibiotic with antimicrobial activity against gram-positive bacteria, including methicillin-resistant and vancomycin-resistant Staphylococcus aureus; Proteomic-based In-Vivo Induced Antigen Technology (PIVIAT) and Proteomic-based Change Mediated Antigen Technology (PCMAT) diagnostic platforms that enable the identification of novel and potentially important gene targets associated with the natural onset and progression of infections, cancers, and other diseases in humans and other living organisms, including plants; and SMaRT Replacement Therapy, which is a painless topical treatment for protection against tooth decay. The company primarily operates in the United States and Mexico. It was formerly known as Oragen, Inc.

Impax Laboratories, Inc. company was founded in 1993 and is headquartered in Hayward, California. mpax Laboratories, Inc. engages in the development and commercialization of bioequivalent and brand-name pharmaceuticals. It operates through two divisions, Global Pharmaceuticals and Impax Pharmaceutical. The Global Pharmaceuticals division develops, formulates, manufactures, and sells controlled release and specialty generic pharmaceutical products. This division offers generic prescription products directly to wholesalers and large retail drug chains; and generic over-the-counter and generic prescription products through unrelated third-party pharmaceutical entities. The Impax Pharmaceutical division develops proprietary brand pharmaceutical products that address central nervous system disorders, including Alzheimer's disease, attention deficit hyperactivity disorder, depression, epilepsy, migraines, multiple sclerosis, Parkinson's disease, and schizophrenia. As of March 10, 2009, the company marketed 70 generic pharmaceuticals representing dosage variations of 24 different pharmaceutical compounds through its Global Pharmaceuticals division, as well as 16 products representing dosage variations of 4 different pharmaceutical compounds through its alliance agreements partners. Impax Laboratories markets and sells its generic pharmaceutical prescription drug products in the continental United States of America and the Commonwealth of Puerto Rico. It has alliance agreements with Teva Pharmaceutical Industries, Ltd.; Wyeth; Schering-Plough Corporation; and DAVA Pharmaceuticals, Inc.

IntelliPharmaCeutics International (IPC) is getting smarter about drug delivery by the second. The pharmaceutical company uses its controlled release drug delivery technology to develop new and generic drug products for enhanced treatment of pain, cardiovascular, and neurological issues. Its products are based on its patented HYPERMATRIX platform, which controls a drug's release time within the gastrointestinal tract. With a diverse pipeline, IPC develops its own proprietary products, as well as ones for third parties, including international clients; it also offers contract manufacturing. In 2009 the formerly private company merged with Vasogen to create the publicly traded IntelliPharmaCeutics International.

Cornerstone Therapeutics Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for the respiratory market in the United States. Its marketed products include SPECTRACEF for the treatment of mild to moderate infections, such as community-acquired pneumonia, acute bacterial exacerbation of chronic bronchitis, pharyngitis and tonsillitis, and uncomplicated skin and skin-structure infections; ZYFLO CR for the prevention and chronic treatment of asthma in adults and children 12 years of age or older; and ALLERX Dose Pack products, which are oral tablets for the temporary relief of symptoms associated with allergic rhinitis.Cornerstone Therapeutics company also markets HYOMAX line of products, which consist of generic formulations of four antispasmodic medications containing the API hyoscyamine sulfate, an anticholinergic for functional intestinal disorders to reduce symptoms, such as those seen in mild dysenteries and diverticulitis; and BALACET 325, APAP 325, and APAP 500 for the relief of mild to moderate pain. In addition, its products under development include SPECTRACEF Once Daily for acute bacterial exacerbations of chronic bronchitis with COPD; SPECTRACEF Suspension for pharyngitis and tonsillitis, and acute otitis media; CRTX 058 for temporary relief of symptoms associated with allergic rhinitis; and CRTX 067 and CRTX 069 for temporary relief of symptoms associated with cough, and upper respiratory symptoms associated with allergies or a cold.

Futura Medical plc company, which develops pharmaceutical and other medical products for sexual dysfunctions in both men and women, uses the DermaSys technology in its MED2002 non-prescription topical gel being developed with GlaxoSmithKline as an erectile dysfunction product. Futura is exploring other applications for DermaSys as MED2002 continues clinical trials. Other products include CSD500, a device to reduce condom slippage, and FLD 500, the company's Female Lubrication Device that is globally marketed and distributed by SSL International.

NovaDel Pharma is developing new ways to deliver popular over-the-counter and prescription drugs...just make sure you don't grab your cologne by mistake. NovaDel company's proprietary oral spray delivery system allows for faster absorption into the bloodstream, in turn producing therapeutic benefits more quickly. NovaDel won FDA approval of its first product, NitroMist (an oral spray formulation of a common angina treatment), in 2006; the company is looking for a partner to market the drug. The company received FDA approval of its ZolpiMist, a spray version of Sanofi-Aventis' insomnia drug Ambien, in 2008. It is also developing spray versions of treatments for nausea, migraine, and central nervous system disorders.

Kreatech Biotechnology company develops tools used by pharmaceutical companies and medical researchers to detect and label RNA, DNA, and proteins. Its labeling kits, DNA probes, and other products are used in applications such as drug development and the diagnosis of disease. The company's investors include 3i Group, Alafi Capital, and Life Sciences Partners. Kreatech has formed alliances with many pharmaceutical and instrumentation firms, including heavyweights such as GE Healthcare Bio-Sciences and PerkinElmer.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.